CRISPR Therapeutics AG Quarterly Weighted Average Number of Shares Outstanding, Diluted from Q1 2016 to Q2 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
CRISPR Therapeutics AG quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q1 2016 to Q2 2024.
  • CRISPR Therapeutics AG Weighted Average Number of Shares Outstanding, Diluted for the quarter ending June 30, 2024 was 84.9M shares, a 7.37% increase year-over-year.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 79.2M shares, a 1.9% increase from 2022.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 77.7M shares, a 3.29% decline from 2021.
  • CRISPR Therapeutics AG annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 80.4M shares, a 21.9% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 84.9M +5.83M +7.37% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 81.8M +3.12M +3.96% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 79.2M +1.47M +1.9% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 79.4M +1.39M +1.79% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 79.1M +1.58M +2.04% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 78.7M +1.58M +2.05% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 77.7M -2.65M -3.29% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 78M +1.73M +2.27% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 77.5M -2.94M -3.65% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 77.1M +2.09M +2.79% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 80.4M +9.11M +12.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 76.3M +6.15M +8.76% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 80.4M +19M +31% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 75M +14.2M +23.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 71.3M +11M +18.3% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-16
Q3 2020 70.1M +12.5M +21.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 61.4M +8.23M +15.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 60.8M +8.75M +16.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q4 2019 60.2M +8.55M +16.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-16
Q3 2019 57.6M +10.2M +21.5% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-16
Q2 2019 53.2M +6.35M +13.5% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-16
Q1 2019 52.1M +6.22M +13.5% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-16
Q4 2018 51.7M +10.1M +24.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-12
Q3 2018 47.4M +7.3M +18.2% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-12
Q2 2018 46.8M +6.95M +17.4% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-12
Q1 2018 45.9M +6.15M +15.5% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-12
Q4 2017 41.6M +6.65M +19% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-25
Q3 2017 40.1M +34.8M +657% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-25
Q2 2017 39.9M +34.4M +632% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-25
Q1 2017 39.7M +34.2M +619% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-25
Q4 2016 35M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 5.29M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 5.45M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 5.53M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.